Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 5 , Pages 403-406 , September 2006

Complete response of bony metastatic bladder urothelial cancer to neoadjuvant chemotherapy and cystectomy

  • Fadi N. Joudi, M.D.

      Affiliations

    • Department of Urology, University of Iowa, Iowa City, IA 52242-1089, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-319-356-7221; fax: +1-319-356-3900.
    • ,
  • Laila Dahmoush, M.D.

      Affiliations

    • Department of Pathology, University of Iowa, Iowa City, IA 52242-1089, USA
    • ,
  • David M. Spector, M.D.

      Affiliations

    • Hematology Oncology Consultants, Davenport, IA 52804, USA
    • ,
  • Badrinath R. Konety, M.D.

      Affiliations

    • Department of Urology, University of Iowa, Iowa City, IA 52242-1089, USA

Received 28 June 2005 ,Revised 19 December 2005 ,Accepted 22 December 2005.

References 

  1. Malkowicz SB . Management of superficial bladder cancer . In:  Walsh PC ,  Retik AB ,  Vaughan ED editor. Campbell’s urology . 8th ed.. Philadelphia (PA): Saunders; 2002;p. 2785–2802
  2. Whitmore WF . Management of invasive bladder neoplasms . Semin Urol . 1983;1:4–10
  3. Matthews PN , Madden M , Bidgood KA , et al.   The clinicopathological features of metastatic superficial papillary bladder cancer . J Urol . 1984;132:904–906
  4. Sengelov L , Kamby C , von der Maase H . Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma . J Urol . 1996;155:111–114
  5. Sternberg CN , Yagoda A , Scher HI , et al.   M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium . J Uol . 1988;139:461–469
  6. Bannowsky A , Wefer B , Naumann M , et al.   “Second line” polychemotherapy in metastatic urothelial cancer of the renal pelvis (Persisting partial remission by 18 treatment cycles of gemcitabine/paclitaxel after 24 treatment cycles) . Urologe A . 2005;44:915–917
  7. Sengelov L , Nielsen OS , Kamby C , et al.   Platinum analogue combination chemotherapy: Cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors (A phase II trial with evaluation of prognostic factors) . Cancer . 1995;76:1797–1803
  8. Saxman SB , Propert KJ , Einhorn LH , et al.   Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study . J Clin Oncol . 1997;15:2564–2569
  9. Dodd PM , McCaffrey JA , Herr H , et al.   Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable metastatic transitional cell carcinoma . J Clin Oncol . 1999;17:2546–2552
  10. Hussain SA , James ND . The systemic treatment of advanced and metastatic bladder cancer . Lancet Oncol . 2003;4:489–497
  11. Bajorin DF , Dodd PM , Mazumdar M , et al.   Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy . J Clin Oncol . 1999;17:3173–3181

PII: S1078-1439(06)00006-8

doi: 10.1016/j.urolonc.2005.12.002

Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 5 , Pages 403-406 , September 2006

Article Tools

* Image Usage & Resolution